Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression

被引:29
|
作者
Rivas-Grajales, Ana Maria [1 ]
Salas, Ramiro [1 ,2 ,3 ,4 ]
Robinson, Meghan E. [5 ,6 ]
Qi, Karen [7 ]
Murrough, James W. [8 ,9 ,10 ]
Mathew, Sanjay J. [1 ,3 ]
机构
[1] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, One Baylor Plaza MS BCM350, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA
[3] Michael E DeBakey VA Med Ctr, Mental Hlth Care Line, Houston, TX USA
[4] Menninger Clin, Houston, TX USA
[5] Baylor Coll Med, Core Adv Magnet Resonance Imaging, Houston, TX 77030 USA
[6] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA
[7] Rice Univ, Dept Cognit Neurosci, Houston, TX USA
[8] Icahn Sch Med Mt Sinai, Dept Psychiat, Depress & Anxiety Ctr Discovery & Treatment, New York, NY 10029 USA
[9] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA
[10] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA
关键词
Habenula; ketamine; resting-state functional MRI; treatment-resistant depression; LATERAL HABENULA; FUNCTIONAL CONNECTIVITY; SYNAPTIC POTENTIATION; DYSFUNCTION; RESPONSES; BOLD;
D O I
10.1093/ijnp/pyaa089
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Ketamine's potent and rapid antidepressant properties have shown great promise to treat severe forms of major depressive disorder (MDD). A recently hypothesized antidepressant mechanism of action of ketamine is the inhibition of N-methyl-D-aspartate receptor-dependent bursting activity of the habenula (Hb), a small brain structure that modulates reward and affective states. Methods: Resting-state functional magnetic resonance imaging was conducted in 35 patients with MDD at baseline and 24 hours following treatment with i.v. ketamine. A seed-to-voxel functional connectivity (FC) analysis was performed with the Hb as a seed-of-interest. Pre-post changes in FC and the associations between changes in FC of the Hb and depressive symptom severity were examined. Results: A reduction in Montgomery-Asberg Depression Rating Scale scores from baseline to 24 hours after ketamine infusion was associated with increased FC between the right Hb and a cluster in the right frontal pole (t = 4.65, P = .03, false discovery rate [FDR]-corrected). A reduction in Quick Inventory of Depressive Symptomatology-Self Report score following ketamine was associated with increased FC between the right Hb and clusters in the right occipital pole (t.5.18, P< .0001, FDR-corrected), right temporal pole (t.4.97, P< .0001, FDR-corrected), right parahippocampal gyrus (t=5.80, P..001, FDR-corrected), and left lateral occipital cortex (t=4.73, P..03, FDR-corrected). Given the small size of the Hb, it is possible that peri-habenular regions contributed to the results. Conclusions: These preliminary results suggest that the lib might be involved in ketamine's antidepressant action in patients with MDD, although these findings are limited by the lack of a control group.
引用
收藏
页码:383 / 391
页数:9
相关论文
共 50 条
  • [41] Intravenous Ketamine Treatment for Adolescents With Treatment-Resistant Depression: Clinical Effects and Impacts on Neural Structure
    Cullen, Kathryn
    Klimes-Dougan, Bonnie
    Lim, Kelvin
    Carstedt, Patricia
    Eberly, Lynn
    Roback, Mark
    Albott, Sophia
    Amatya, Palistha
    Mueller, Bryon
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S493 - S494
  • [42] Sleep alterations in treatment-resistant depression patients undergoing ketamine treatment
    Kwasny, Aleksander
    Cubala, Wieslaw Jerzy
    Wlodarczyk, Adam
    Pastuszak, Krzysztof
    PHARMACOLOGICAL REPORTS, 2024, 76 (06) : 1325 - 1332
  • [43] Role of the Pharmacist in Managing Treatment-Resistant Depression: A Focus on Ketamine
    Liu, Linda Xing Yu
    Golts, Marina
    Fernandes, Virginia
    PHARMACY, 2021, 9 (03)
  • [44] Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine
    Garakani, Amir
    JOURNAL OF PSYCHIATRIC PRACTICE, 2021, 27 (06) : 496 - 497
  • [45] Gene Expression and Ketamine Response in Subjects With Treatment-Resistant Depression
    Mohazzab-Hosseinian, Sahra
    Kadriu, Bashkim
    Zandi, Peter
    Zarate, Carlos
    Goes, Fernando
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 318 - 319
  • [46] Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression
    O'Brien, Brittany
    Green, Charles E.
    Al-Jurdi, Rayan
    Chang, Lee
    Lijffijt, Marijn
    Iqbal, Sidra
    Iqbal, Tabish
    Swann, Alan C.
    Mathew, Sanjay J.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 16
  • [47] Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases
    Bartova, Lucie
    Vogl, Sonja E.
    Stamenkovic, Mara
    Praschak-Rieder, Nicole
    Naderi-Heiden, Angela
    Kasper, Siegfried
    Willeit, Matthaeus
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 (11) : 2183 - 2184
  • [48] A randomised, open-label, pragmatic pilot comparison of oral and intravenous ketamine in treatment-resistant depression
    Kumar, P. N. Suresh
    Menon, Vikas
    Andrade, Chittaranjan
    ASIAN JOURNAL OF PSYCHIATRY, 2024, 99
  • [49] Symptom modulation and tolerability of intravenous ketamine in treatment-resistant bipolar depression: A retrospective study
    Cuomo, Alessandro
    Pardossi, Simone
    Barilla, Giovanni
    Carmellini, Pietro
    Firenzuoli, Bernardo
    Tarantino, Francesca
    Tinturini, Rebecca
    Fagiolini, Andrea
    JOURNAL OF AFFECTIVE DISORDERS, 2025, 376 : 76 - 83
  • [50] Cognitive Behavior Therapy to Prevent Relapse Following Intravenous Ketamine in Treatment-resistant Depression
    Wilkinson, Samuel T.
    Ostroff, Robert
    Sanacora, Gerard
    Fasula, Madonna
    Griepp, Matthew
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 210S - 210S